Zydus Lifesciences Enters Into Pact With Japan's Takeda Pharmaceuticals
The drug, which treats the gastroesophageal reflux disease, will be marketed under the brand name Vault in India.
Zydus Lifesciences Ltd. on Wednesday said it has inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD).
The company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Co. to market the novel potassium competitive acid blocker Vonoprazan in India, the drug firm said in a statement.
The drug will be marketed under the brand name Vault in the country, it added.
Under the terms of this agreement, Zydus will be marketing the drug in India.
"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum," Zydus Lifesciences Managing Director Sharvil Patel said.
Vonoprazan is approved by the Drugs Controller General of India for the treatment of adults with reflux esophagitis and other acid peptic disorders.
